Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy
- 1 January 2007
- journal article
- review article
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 13 (1) , 30-39
- https://doi.org/10.1097/ppo.0b013e31803c73cc
Abstract
The histone deacetylase inhibitors are a new class of agents that are currently in various stages of clinical development. Clinical trials have demonstrated activity, urging further investigation. At the same time, it has been discovered that these agents have their own challenges. In this review, we discuss clinical data gathered to date, combination therapies designed to increase efficacy, and toxicities attributed to this new class of agents.Keywords
This publication has 103 references indexed in Scilit:
- Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaBlood, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitorBlood, 2006
- Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group ReportJournal of Clinical Oncology, 2006
- Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell linesInvestigational New Drugs, 2006
- Restoration of Tamoxifen Sensitivity in Estrogen Receptor–Negative Breast Cancer Cells: Tamoxifen-Bound Reactivated ER Recruits Distinctive Corepressor ComplexesCancer Research, 2006
- Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell LymphomaClinical Cancer Research, 2006
- Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01British Journal of Cancer, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Regulation of cellular processes by PPARγ ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expressionBiochemical Society Transactions, 2004